425: Nano Dimension to Combine with Infinite Epigenetics

Nano Dimension Ltd. has entered into a non-binding term sheet to combine with Infinite Epigenetics, an AI-powered preventive health and diagnostics company, aiming to create a Nasdaq-listed entity focused on AI and epigenetics.

Summary

• Nano Dimension Ltd. (Nano) has signed a non-binding term sheet to combine with Infinite Epigenetics (Infinite), an AI-powered preventive health and diagnostics company.
• The proposed transaction is structured as a stock-for-stock merger, with Infinite Epigenetics expected to operate under its own name and trade on the Nasdaq Capital Market under the ticker symbol IEAI.
• Existing Nano Dimension shareholders are expected to retain a meaningful minority ownership in the combined company, with the valuation of Nano shares reflecting a 20% premium to its estimated net cash at closing.
• The combined company is projected to have over $400 million in cash at closing, intended to provide ample runway without immediate need for additional capital raises.
• Infinite Epigenetics focuses on using AI and epigenetic data to predict and detect chronic diseases earlier, with initial targets including cardiovascular disease, Type 2 diabetes, COPD, and MASLD.
• The transaction is subject to the negotiation and execution of a definitive agreement, satisfactory due diligence, and shareholder and regulatory approvals.
• Nano Dimension will continue to operate its remaining product lines while advancing the strategic plan and working towards definitive transaction documents.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as Nano Dimension is strategically pivoting to a high-growth sector with a well-capitalized and promising company, though the transaction is still subject to definitive agreement and approvals.

Positives

• Nano Dimension is deploying its capital base and Nasdaq listing into a high-growth healthcare AI opportunity.
• Infinite Epigenetics has a revenue-generating platform with a large, growing addressable market and a proprietary biological AI foundation model.
• The combined company is expected to have over $400 million in cash at closing, providing significant financial flexibility.
• Existing Nano Dimension shareholders are expected to retain a meaningful minority ownership with a valuation reflecting a 20% premium to Nano's estimated net cash.
• Infinite Epigenetics has a strong leadership team with a track record of building and exiting companies.
• The transaction is expected to create a category-defining company at the intersection of healthcare, biological data, and AI.
• Infinite Epigenetics has collected over 120,000 epigenetic samples and developed a proprietary DNA methylation dataset.

Negatives

• The transaction is non-binding and subject to the successful negotiation of a definitive agreement and satisfaction of closing conditions.
• There is a risk that the transaction may not be consummated at all.
• Nano Dimension shareholders will retain a minority ownership, meaning they will not have controlling interest in the combined entity.
• The valuation of Infinite Epigenetics is based on a stated value of $890 million less a premium, which is subject to final negotiation.
• Nano Dimension will reimburse Infinite for up to $3 million in expenses if a definitive agreement is not executed by the EGM Date under certain conditions.

Risks

• The risk that Nano Dimension and Infinite Epigenetics are unable to negotiate and enter into a definitive agreement.
• The risk that conditions to closing, including necessary shareholder approvals, are not satisfied.
• Uncertainties regarding the timing of the consummation of the transaction.
• The effect of the announcement on the ability of both companies to operate their businesses and retain key personnel.
• Risks related to the failure or delay in obtaining necessary governmental or regulatory approvals.
• Changes in the exchange ratio could result in Nano shareholders owning more or less of the combined company than anticipated.
• Risks related to the market price of Nano Dimension's shares relative to the value suggested by the term sheet.
• Unexpected costs, charges, or expenses resulting from the transaction.
• The potential for any event, change, or circumstance that could give rise to the termination of the term sheet or definitive agreement.
• The possibility that Nano shareholders may never receive any proceeds from the disposition of legacy assets.
• Changes in demand for either company's products and services.
• Global market, political, and economic conditions.
• The impact of changes in law and government regulations.
• Competition in the epigenetics health industry.
• The risk of litigation, including proceedings related to the transaction.
• The impact of rapid technological change in the epigenetics health industry.

Future Outlook

The combined company, operating as Infinite Epigenetics, is expected to trade on Nasdaq under the ticker IEAI. The company aims to leverage AI and epigenetic data to become a leader in preventive health and diagnostics, with a focus on chronic diseases. The projected cash at closing is intended to provide ample runway for growth without immediate need for additional capital raises. The transaction is expected to close by the end of the year.

Management Comments

• "Infinite Epigenetics represented the most attractive opportunity for us to enhance shareholder value."
• "We believe Infinite Epigenetics has the potential to become a category-defining company at the intersection of healthcare, biological data and AI, and that the proposed business combination would create a clear and compelling path for long-term shareholder value creation."
• "The proposed business combination with Infinite Epigenetics represents the next major step in Nano's strategic plan."
• "We believe Infinite Epigenetics offers a compelling opportunity with meaningful long-term potential, and one that we are confident can deliver lasting value for our shareholders."
• "We believe the most valuable healthcare AI platforms will be built on proprietary biological data, leveraging AI for novel discoveries and insights."
• "Our mission is to help move healthcare from reactive to proactive by giving clinicians and individuals earlier insight into what the body is signaling, often before symptoms appear."
• "This is the right opportunity at the right time."
• "We believe Infinite is exactly the kind of AI-driven healthcare platform that can shift the market and create meaningful value for our shareholders."
• "Our job is to earn that confidence. We will do that by executing with discipline, deploying your capital responsibly, and building around the foundation already in place: real technology, real data, real revenue, and a real platform."

Industry Context

StockSavvy.ai notes that this transaction signifies a strategic pivot for Nano Dimension from advanced digital manufacturing to the high-growth healthcare AI and diagnostics sector. The move aligns with broader industry trends of leveraging AI and big data for personalized and preventive medicine, particularly in the epigenetics space, which is gaining traction as a key indicator of health and disease risk.

Comparison to Industry Standards

• Exact Sciences is cited as a precedent for molecular diagnostics scaling in the public markets with a single chronic disease test.
• GRAIL is mentioned as a precedent for methylation-based multi-disease detection from blood.
• Tempus AI is highlighted as a precedent for proprietary clinical data combined with AI creating a public-market platform.
• Infinite Epigenetics' models show AUCs of 0.85-0.96 for major chronic diseases, which are presented as strong performance compared to published comparator ranges for other diagnostic tools (e.g., FIB-4 for MASLD, PREVENT for CVD, FINDRISC for T2D, symptom-based case-finding for COPD).
• The company's initial focus on Type 2 Diabetes, Cardiovascular Disease, MASLD, and COPD addresses markets with significant burdens, with a total addressable market (TAM) estimated at $94 billion for these indications in the U.S.

Management Changes

Corporate Governance

Legal Proceedings

• The filing mentions the risk of litigation, including any proceedings that may be instituted against Nano or Infinite related to the transaction.

Related Party Transactions

• Information regarding the compensation and security holdings of Nano Dimension's directors and executive officers is referenced as being set forth in its Annual Report and updated in SEC filings.

Stakeholder Impact

• Shareholders: Expected to retain a meaningful minority ownership in the combined company, with a valuation reflecting a premium to Nano's net cash. They will also receive a contingent value right related to legacy assets.
• Employees: The announcement may create uncertainty regarding future roles and operations for employees of both Nano Dimension and Infinite Epigenetics.
• Management: Key management from Infinite Epigenetics, including CEO Dr. Matthew Dawson, will lead the combined company. Nano Dimension's management will transition roles.
• Creditors: The term sheet mentions that the Break Fee Escrow will not be subject to any lien, security interest, setoff, or attachment, and shall not be reachable by Nano's creditors.

Next Steps

• Negotiate and execute a definitive agreement for the business combination.
• Conduct confirmatory due diligence on Infinite Epigenetics.
• Obtain necessary Board of Directors and shareholder approvals.
• File a registration statement on Form S-4 with the SEC.
• File a proxy statement with the SEC for the extraordinary general meeting.
• Hold the extraordinary general meeting of shareholders on July 31, 2026.
• Complete Nano Dimension's re-domestication to the United States.
• Obtain regulatory approvals.
• List the combined company's common stock on Nasdaq.
• Close the transaction by the end of the year.

Key Dates

Recommendation

The transaction represents a significant strategic shift for Nano Dimension into a high-growth sector, which is positive. However, the deal is still non-binding and subject to numerous conditions, including due diligence and shareholder approval. While Infinite Epigenetics shows promise, the execution risk and the fact that Nano shareholders will become minority holders warrant a 'hold' recommendation until the definitive agreement is signed and further details emerge.

Keywords

Nano Dimension, Infinite Epigenetics, Business Combination, Merger, AI, Epigenetics, Preventive Health, Diagnostics, Healthcare, Nasdaq, Term Sheet, SEC Filing, 8-K